SAN JUAN CAPISTRANO, Calif.–(BUSINESS WIRE)–Allegro Ophthalmics, LLC today announced completion of enrollment in its Phase 2b trial that is evaluating the safety and efficacy of Luminate® (ALG-1001) in patients with diabetic macular edema.
Category: Business
Research and Markets: US & Europe Corneal Topographers Market Report – Analysis, Technologies & Forecasts 2016-2020
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/zcs6hd/us_and_europe) has announced the addition of the “US & Europe Markets for Corneal Topographers – 16 Countries (2010-2020)” report to their offering. The US & Europe Markets for Slit Lamps covers 16 Countries and includes detailed and comprehensive information and data on Pacido Ring Corneal Topographers as well as Scheimpflug cameras. Corneal topography is also known as videokeratography or
Ocata Reports the Publication of Data about the Generation of Corneal Endothelial Cells from Human Pluripotent Stem Cells
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (OCAT), a leader in the field of regenerative medicine, reported today that early research was published in the journal PLOS One (online, December 21, 2015) by Ocata and its collaborators at the University of Miami, UCSD, and Stanford University. The publication presents a method for generating scalable amounts of human embryonic stem cell derived corneal endothelial cells (hESC-CEC). “Disease and injury to the cornea are leading cau
CooperVision & Its Employees Donate $125,000 to Optometry Giving Sight’s 2015 World Sight Day Challenge
PLEASANTON, Calif.–(BUSINESS WIRE)–Employees from contact lens manufacturer CooperVision have donated $125,000 to Optometry Giving Sight in support of the 2015 World Sight Day Challenge.
Research and Markets: Refractive Surgery Devices Pipeline Review, 2015 – Analysis, Technologies & Forecasts
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/mtrj6d/refractive) has announced the addition of the “Refractive Surgery Devices – Pipeline Review, 2015” report to their offering. The report provides comprehens…
Guardian Announces Agreement to Acquire Leading Government Benefit Provider
NEW YORK–(BUSINESS WIRE)–Guardian has entered into a definitive agreement to acquire Avēsis, a leading government contract vision, dental and hearing provider
Research and Markets: Europe Cataract Market Report – Analysis, Technologies & Forecasts 2015-2020
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/tv9nwh/europe_cataract) has announced the addition of the “Europe Cataract Market Highlights – 2015” report to their offering. The latest research, ‘Europe Catara…
Research and Markets: Europe Conjunctivitis Market Report – Analysis, Technologies & Forecasts 2015-2020
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/mrvjdf/europe) has announced the addition of the “Europe Conjunctivitis Market Highlights – 2015” report to their offering. The latest research, ‘Europe Conjuncti…
Research and Markets: Europe Glaucoma Market Report – Analysis, Technologies & Forecasts 2015-2020
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/kdpbgn/europe_glaucoma) has announced the addition of the “Europe Glaucoma Market Highlights – 2015” report to their offering. The latest research, ‘Europe Glauco…
Research and Markets: Europe Dry Eye Syndrome Market Report – Analysis, Technologies & Opportunities 2015-2020
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/nnqbmp/europe_dry_eye) has announced the addition of the “Europe Dry Eye Syndrome Market Highlights – 2015” report to their offering. The latest research, ‘Europe…
Research and Markets: Europe Age-related Macular Degeneration Market Report – Analysis & Forecasts 2015-2020
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/62rrm7/europe) has announced the addition of the “Europe Age-related Macular Degeneration Market Highlights – 2015” report to their offering. The latest research,…
XL-Protein and Easton Pharmaceutical Sign License Agreement to Develop Biopharmaceuticals Using PASylation® Technology
FREISING, Germany & CHENGDU, China–(BUSINESS WIRE)–XL-protein and Easton Pharmaceutical Sign License Agreement to Develop Biopharmaceuticals Using PASylation® Technology
Resumen: NovaTears® estabiliza de forma significativa la película lagrimal y alivia los síntomas del síndrome del ojo seco en pacientes con la enfermedad del ojo seco evaporativo
HEIDELBERG, Alemania–(BUSINESS WIRE)–Un nuevo estudio ha demsotrado que NovaTears®, el primer colirio tópico disponible a la venta de Novaliq GmbH para el tratamiento de la enfermedad del ojo seco evaporativo, ha mejorado de manera significativa cuatro o cinco medidas asociadas con la enfermedad. El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción es solamente un medio de ayuda y deberá ser comparada con el texto en idioma original, que es la única
Samenvatting: NovaTears stabiliseert traanfilm en vermindert droogte bij mensen met keratoconjunctivis sicca door traanverdamping
HEIDELBERG, Duitsland–(BUSINESS WIRE)–NovaTears, de eerste commercieel verkrijgbare oogdruppel van Novaliq GmbH voor de behandeling van keratoconjunctivis sicca (droge ogen) als gevolg van traanverdamping, zorgt voor significante verbeteringen van vi…
$4 Million Contributed to Establish Chair for The Vision Center at Children’s Hospital Los Angeles
LOS ANGELES–(BUSINESS WIRE)–Two philanthropic gifts, totaling $4 million, have been pledged in support of The Vision Center at Children’s Hospital Los Angeles, an international referral center for children with complex eye diseases. A $2 million gift from the Larry & Celia Moh Foundation to The Vision Center will help establish the A. Linn Murphree Retinoblastoma Program Chair. CHLA ophthalmologist A. Linn Murphree, MD, established the retinoblastoma center at Children’s Hospital Los Ange
NovaTears® Significantly Stabilizes the Tear Film and Relieves Dry Eye Symptoms in Patients with Evaporative Dry Eye Disease
HEIDELBERG, Germany–(BUSINESS WIRE)–NovaTears, from Novaliq GmbH, was found to significantly improve four of five measures associated with evaporative dry eye disease, new research shows. It was also shown to be safe and well tolerated.
Clinical Data from ReVision Optics’ Raindrop Near Vision Inlay Featured in Two Presentations at the OIS@AAO Conference
LAKE FOREST, Calif.–(BUSINESS WIRE)–ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces that clinical data from its Raindrop® Near Vision Inlay for the treatment of presbyopia was the subject of two presentations at the 2015 OIS@AAO conference, held last month in Las Vegas. At the conference, John Kilcoyne, ReVision Optics President and Chief Executive Officer, presented an overview of clinical data from 344 patients followed for 24 months
Clinical Data from ReVision Optics’ Raindrop Near Vision Inlay Featured in Two Presentations at the OIS@AAO Conference
LAKE FOREST, Calif.–(BUSINESS WIRE)–ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces that clinical data from its Raindrop® Near Vision Inlay for the treatment of presbyopia was the subject of two presentations at the 2015 OIS@AAO conference, held last month in Las Vegas. At the conference, John Kilcoyne, ReVision Optics President and Chief Executive Officer, presented an overview of clinical data from 344 patients followed for 24 months
NovaBay Declares Reverse Stock Split
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) (“NovaBay” or the “Company”), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market, today announced that, pursuant to authorization provided by the Company’s stockholders at the Company’s December 11, 2015, special stockholder meeting, and in order to meet the continued listing standards of the NYSE MKT, the Company’s Board of
Ignyta Announces Initiation of STARTRK “Next Generation” Phase 1/1b Pediatric Clinical Trial of Entrectinib
SAN DIEGO–(BUSINESS WIRE)–Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the initiation of STARTRK-NG, a new pediatric Phase 1/1b clinical trial of entrectinib, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumors that harbor activating alterations to NTRK1, NTRK2, NTRK3, ROS1 or ALK. STARTRK-NG (which stands for “Studies of Tumor Alterations Responsive to Targeting Receptor Kinases – Next Generation”) is a multicenter, open